Making a difference

STADA is very active in the field of biosimilars. Our aim is to help patients gain access to modern therapies by developing products that meet their medicinal needs more affordably on a long-term basis.

More opportunities

Figures suggest that expenditure on medicinal products will be up to €1.3 trillion by 2020. In the EU, biosimilars are approved following a stringent regulatory process. When correctly developed and prescribed, they represent a fantastic opportunity to give more patients access to biologic therapies in the EU and worldwide. They also reduce costs and contribute to more sustainable healthcare systems.

Silapo®

Silapo® is a biosimilar injection that is used to treat low red blood cell count, known as anemia, in patients who have chronic renal failure or other kidney problems. It can also be used to reduce the need for blood transfusions by treating anemia in patients who need to undergo chemotherapy to treat certain types of cancers.

Movymia®

Movymia® is used for the treatment of men or post-menopausal women with osteoporosis, a condition that weakens bones, with a high risk of fracture.

Oyavas®

Oyavas® (bevacizumuab) is an injectable medicine used alone or in combination in cancer patients to treat certain advanced or metastatic types of cancers like colorectal cancer, NSCLC (Non-Small Cell Lung Cancer), RCC (Renal Cell Carcinoma), breast cancer or ovarian cancer. Please note that Oyavas® is currently under the EMA registration process.

Cegfila®

Cegfila® contains the active substance PEGfilgrastim and is an injectable medicine used for treatment of neutropenia (low levels of a certain type of white blood cell called neutrophils), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever).

Disclaimer

Please note, the product information on this website is meant to provide an overview of the STADA biosimilar portfolio to a global audience. Not all products are available in all countries. If you would like to find out whether a specific product is available in your market, please contact us via email or call +49 6101 603-0 (English and German).